Furthering development of cutting-edge technology for protein analysis
15 February 2013
International biotechnology company AyoxxA Biosystems and NUS’ Department of Bioengineering will be working together to further develop Ayoxxa’s proprietary platform technology and scale up production of its novel bead-based biochips as the company moves towards commercialisation. The two organisations inked a Research Collaboration Agreement last month to formalise their partnership.
On this two-year collaboration, Assistant Professor Dieter Trau from NUS’ Faculty of Engineering, who is also AyoxxA’s Chief Scientific Officer, said that it will extend the long term cooperation between NUS and AyoxxA.
“This has been already a very fruitful endeavour to develop an initial idea at the NUS Department of Bioengineering to the commercialisation of our chip technology with AyoxxA,” noted Dr Trau.
AyoxxA’s In-situ Encoded Bead-based Arrays (IEBA), licensed from NUS, allow small samples of multiple proteins to be measured simultaneously. Compared to current bead-based microarrays, the IEBA makes protein analysis simpler and more efficient.
“The fact that NUS technologies are being commercialised into applications to boost biomedical sciences research that could ultimately save lives, is indeed heartening,” said Ms Irene Cheong, Director of the NUS Industry Liaison Office.
An NUS spin-off, AyoxxA is supported by NUS Enterprise. Since its inception in 2010, the company based in Singapore and Germany has received multiple grants, including funding from the National Research Foundation, the SMART Innovation Centre and SPRING’s Technology Enterprise Commercialisation Scheme.
- Read straight from NUS